Ikarian Capital’s Definium Therapeutics DFTX Stock Holding History

Ikarian Capital’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-58,803	Closed	-$1.11M	–	179
2026 Q1	$1.11M	Hold	58,803	–	–	0.09%	111
2025 Q4	$787K	Sell	58,803 -3,888	-6%	-$48.1K	0.06%	131
2025 Q3	$739K	Hold	62,691	–	–	0.07%	128
2025 Q2	$407K	Hold	62,691	–	–	0.08%	95
2025 Q1	$367K	Hold	62,691	–	–	0.05%	123
2024 Q4	$436K	Buy	62,691 +210	+0.3%	+$1.45K	0.06%	132
2024 Q3	$356K	Sell	62,481 -100,000	-62%	-$696K	0.05%	123
2024 Q2	$1.17M	Sell	162,481 -135,000	-45%	-$1.18M	0.2%	69
2024 Q1	$2.8M	Sell	297,481 -302,519	-50%	-$1.72M	0.31%	75
2023 Q4	$2.2M	Buy	+600,000	New	+$1.81M	0.21%	83
2022 Q3	–	Sell	-7,064	Closed	-$68K	–	143
2022 Q2	$68K	Hold	7,064	–	–	0.01%	133
2022 Q1	$118K	Buy	7,064 +397	+6%	+$6.89K	0.02%	178
2021 Q4	$138K	Buy	+6,667	New	+$213K	0.02%	166

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Ikarian Capital's DFTX Position: Q2 2026 in Review

Ikarian Capital sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 58,803 shares — an estimated $1.11M sold.

Ikarian Capital first reported a position in DFTX in Q4 2021 and held it in 13 quarters. The position peaked at $2.8M in Q1 2024. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Ikarian Capital reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
Ikarian Capital sold 58,803 Definium Therapeutics shares in Q2 2026, an estimated $1.11M.
Ikarian Capital first reported a position in Definium Therapeutics in Q4 2021 and held it in 13 quarters.
Ikarian Capital's Definium Therapeutics position peaked at $2.8M in Q1 2024.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.